Structure-based Inhibitor Design for the Intrinsically Disordered Protein c-Myc

94Citations
Citations of this article
185Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Intrinsically disordered proteins (IDPs) are associated with various diseases and have been proposed as promising drug targets. However, conventional structure-based approaches cannot be applied directly to IDPs, due to their lack of ordered structures. Here, we describe a novel computational approach to virtually screen for compounds that can simultaneously bind to different IDP conformations. The test system used c-Myc, an oncoprotein containing a disordered basic helix-loop-helix-leucine zipper (bHLH-LZ) domain that adopts a helical conformation upon binding to Myc-associated factor X (Max). For the virtual screen, we used three binding pockets in representative conformations of c-Myc370-409, which is part of the disordered bHLH-LZ domain. Seven compounds were found to directly bind c-Myc370-409 in vitro, and four inhibited the growth of the c-Myc-overexpressing cells by affecting cell cycle progression. Our approach of IDP conformation sampling, binding site identification, and virtual screening for compounds that can bind to multiple conformations provides a useful strategy for structure-based drug discovery targeting IDPs.

Cite

CITATION STYLE

APA

Yu, C., Niu, X., Jin, F., Liu, Z., Jin, C., & Lai, L. (2016). Structure-based Inhibitor Design for the Intrinsically Disordered Protein c-Myc. Scientific Reports, 6. https://doi.org/10.1038/srep22298

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free